Summary of seasonal and post contact prophylaxis with neuraminidase inhibitors
| Reference | Prophylaxis treatment | Duration | Subjects | Age yrs | Protective efficacy and comments |
| 97 | Zanamivir 10 mg inhaled b.i.d | 4-week seasonal over outbreak | 1107 | 18–69 | 67% against laboratory-confirmed influenza infection, 84% against clinical illness. |
| 98 | Oseltamivir 75 mg once daily or b.i.d | 6/52 seasonal study | 1559 | 18–65 | 74% against laboratory-confirmed influenza infection, no difference between once daily and b.i.d. no emergence of resistance. |
| 99 | Oseltamivir 75 mg once daily | 6/52 seasonal study in nursing home | 548 | Mean of 82 | 92% in prevaccinated group 8 reduction in complications. |
| 100 | Oseltamivir 75 mg once daily | Household contacts 5/7 | 377 households | Healthy adults | 82% |